comparemela.com
Home
Live Updates
Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD) : comparemela.com
Saol Therapeutics Announces Enrollment Achievement in Pivotal Phase 3 Trial for Rare Mitochondrial Disease - Pyruvate Dehydrogenase Complex Deficiency (PDCD)
/PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the pivotal Phase 3 clinical trial evaluating...
Related Keywords
Ireland ,
Dublin ,
Connecticut ,
United States ,
Bermuda ,
Medosome Biotec ,
David Penake ,
Philipe Yeske ,
Peter Stacpoole ,
United Mitochondrial Disease Foundation ,
Professor Of Medicine At University Florida ,
University Of Florida ,
Science Alliance ,
Sodium Dichloroacetate ,
Pyruvate Dehydrogenase Complex Deficiency ,
Saol Therapeutics ,
Principal Investigator ,
Alliance Officer ,
Pyruvate Dehydrogenase Complex ,
Observer Reported Outcome ,
comparemela.com © 2020. All Rights Reserved.